Xencor (NASDAQ:XNCR) Sets New 1-Year Low - Here's Why

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $8.15 and last traded at $8.48, with a volume of 78303 shares changing hands. The stock had previously closed at $8.69.

Analyst Upgrades and Downgrades

XNCR has been the subject of several recent research reports. StockNews.com lowered Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Wells Fargo & Company cut their target price on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $34.38.

Xencor Price Performance

The stock has a 50 day moving average of $13.07 and a 200-day moving average of $19.09. The stock has a market capitalization of $601.75 million, a P/E ratio of -2.67 and a beta of 0.90. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR - Get Free Report) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.19. The business had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. On average, equities research analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xencor

Large investors have recently added to or reduced their stakes in the stock. FMR LLC grew its stake in Xencor by 315.5% in the third quarter. FMR LLC now owns 16,764 shares of the biopharmaceutical company's stock worth $337,000 after purchasing an additional 12,729 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Xencor by 18.6% during the third quarter. Jane Street Group LLC now owns 168,431 shares of the biopharmaceutical company's stock valued at $3,387,000 after buying an additional 26,473 shares during the period. XTX Topco Ltd raised its holdings in shares of Xencor by 113.2% in the third quarter. XTX Topco Ltd now owns 22,080 shares of the biopharmaceutical company's stock valued at $444,000 after acquiring an additional 11,725 shares in the last quarter. Barclays PLC raised its holdings in shares of Xencor by 100.7% in the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock valued at $3,128,000 after acquiring an additional 78,066 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Xencor by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company's stock worth $29,273,000 after acquiring an additional 17,658 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.